Characteristics of Glargine in Type 2 Diabetics

Completed · Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

The study is to determine the dose response relationship of insulin glargine in type 2 diabetes over a 24-hour period and measuring the differences in glucose production among the differing doses of glargine. Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes will show differing effects on endogenous glucose production, glucose disposal and carbohydrate and lipid flux.

Key facts

Study ID

NCT00574912

Run by

Vanderbilt University Medical Center

People needed

20

Starts

2007-03-01

Expected to finish

2010-01-01

Last updated by the study team

2017-04-17

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 12 adults (males or females) with type 2 diabetes for at least six (6) months. May be using oral agents (SUs, metformin, acarbose or glitinides) with or without insulin.
• HgbA1c 7 -12%
• Age 18-70 years
• BMI 27-40 kg/m²

You may not qualify if…

• Any past or present clinically relevant abnormality, medical condition, or circumstance making the subject unsuitable for participation in the study
• Evidence of hepatic, renal or cardiac failure
• Abnormal results following screening tests
• Pregnant or lactating females or females of childbearing potential who are unwilling to abstain from sexual intercourse or use reliable, medically accepted methods of contraception
• Currently using TZDs
• History of alcoholism or drug abuse within 12 months of the study

Where it is running

• Vanderbilt University — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.